Stocks and Investing
Stocks and Investing
Wed, April 24, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, April 23, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Reiterated (BEAM) at Buy and Held Target at $57 on, Apr 23rd, 2024
David Nierengarten of Wedbush, Reiterated "Beam Therapeutics Inc." (BEAM) at Buy and Held Target at $57 on, Apr 23rd, 2024.
David has made no other calls on BEAM in the last 4 months.
There are 4 other peers that have a rating on BEAM. Out of the 4 peers that are also analyzing BEAM, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $35 on, Wednesday, February 28th, 2024
- Gena Wang of "Barclays" Maintained at Hold with Increased Target to $42 on, Wednesday, February 28th, 2024
These are the ratings of the 2 analyists that currently disagree with David
- Kostas Biliouris of "BMO Capital" Maintained at Buy and Held Target at $57 on, Wednesday, March 27th, 2024
- Eric Joseph of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $40 on, Monday, January 29th, 2024
Contributing Sources